Form 4: NeoGenomics Director Equity Transaction Update
Statement of Changes in Beneficial Ownership
Director David Brian Perez acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units.
Summary
- Director David Brian Perez exercised and vested 23,077 restricted stock units (RSUs) into common stock on June 1, 2026.
- Following the transaction, the director holds 56,967 shares directly and 10,000 shares indirectly via a family trust.
- The director was also granted new equity compensation consisting of 11,069 stock options at a strike price of $10.52 and 15,970 RSUs.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity vesting.
Positives
- Director maintains significant skin in the game with a total beneficial ownership of 66,967 shares.
- Equity grants align director incentives with long-term shareholder value creation.
Negatives
- None identified; this is a standard compensatory equity filing.
Risks
- Future share price volatility may impact the value of the newly granted stock options and RSUs.
Future Outlook
The filing indicates ongoing equity-based compensation for the director, with new options and RSUs vesting in June 2027.
Industry Context
StockSavvy.ai notes that routine equity compensation filings for directors are standard practice in the biotechnology and diagnostics sector to ensure alignment between board members and shareholders.
Comparison to Industry Standards
- The equity compensation structure is consistent with standard corporate governance practices for mid-cap healthcare companies.
- Director ownership levels are typical for non-executive board members in the diagnostic testing industry.
Related Party Transactions
- Disclosure of indirect ownership through the Perez Joint Revocable Trust.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine compensatory transaction.
Next Steps
- Vesting of new stock options on June 1, 2027.
- Vesting of new restricted stock units on June 1, 2027.
Key Dates
| Date | Description |
|---|---|
| 2016-12-09 | Date of the Perez Joint Revocable Trust agreement. |
| 2026-06-01 | Date of earliest transaction involving RSU vesting and new equity grants. |
| 2026-06-03 | Date of filing. |
Keywords
NeoGenomics, NEO, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.